Thyroid Eye Disease — Management

Overview: Two Problems, Two Timelines

Thyroid eye disease runs a biphasic course. An active inflammatory phase comes first: orbital fibroblast activity, glycosaminoglycan deposition, and tissue edema are all still underway, and all still respond to anti-inflammatory or immunomodulatory therapy. A chronic, fibrotic "burnt-out" phase follows. By then the inflammation has resolved, but the anatomic damage it left behind (muscle fibrosis, lid retraction, proptosis) is fixed and no longer responds to medical treatment. The Clinical Activity Score is what separates the two phases in practice, and it should drive the choice at every visit. A patient with high activity gets medical therapy first. A stable, inactive patient with residual deformity is a surgical candidate.

Medical Therapy for Active Disease

IV Corticosteroids

For active, moderate-to-severe TED, high-dose intravenous corticosteroids (pulse methylprednisolone) are first-line. They're favored over oral steroids because they act faster and carry a better efficacy and safety profile at the doses TED requires.

Teprotumumab

Teprotumumab works by a different mechanism: it's a monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-1R), which sits on orbital fibroblasts alongside the TSH receptor. IGF-1R signaling amplifies the same fibroblast activation that TSH receptor antibodies drive, so blocking it quiets orbital inflammation and tissue expansion at the cellular source. That's a targeted mechanism, not the broad immunosuppression corticosteroids rely on.

Teprotumumab's most serious adverse effect is sensorineural hearing loss. Trial rates sit near 10%, but real-world audiometric studies have found otologic symptoms (tinnitus, ear fullness, muffled hearing) in a much larger share of treated patients, and a prior history of hearing loss raises the risk further. Baseline and periodic audiometry are recommended during treatment. Tinnitus and ear fullness usually resolve after the infusions stop; hearing loss itself often does not.

Compressive Optic Neuropathy

The most vision-threatening complication of TED is compressive (dysthyroid) optic neuropathy. Its mechanism explains why it strikes at the back of the orbit specifically. The orbital apex is the narrowest point in the entire orbit: the optic nerve, extraocular muscles, and vessels all converge there before passing through the optic canal. When the medial and inferior rectus muscles enlarge from TED-driven inflammation, they crowd this already-tight space and press the optic nerve against the surrounding bone. This apex-crowding mechanism is distinct from proptosis and can occur without it: crowding is about muscle bulk at the narrowest point of the orbit, not about how far forward the globe has moved.

Because compressive optic neuropathy threatens permanent vision loss, catching it early matters. Color vision testing (commonly Ishihara plates) is a sensitized screen for exactly this: subtle color vision impairment can show up before visual acuity measurably declines. Pupillary and visual field assessment round out the early workup, but color vision is the more sensitive warning sign of the three.

Surgical Rehabilitation

Once TED is stable and inactive (low CAS), residual anatomic deformity (proptosis, restrictive strabismus, lid retraction) is addressed surgically. The order is fixed: orbital decompression, then strabismus surgery, then eyelid surgery.

This staged sequence exists because each procedure can shift the anatomic starting point the next one depends on. Orbital decompression removes one or more orbital walls to create volume for the crowded contents, relieving proptosis (or, urgently, compressive optic neuropathy), but it also changes globe position and can shift ocular alignment and eyelid position along with it. New-onset diplopia is a well-known complication of decompression, since moving the globe changes the vector pull of every extraocular muscle, even ones the surgeon never touched. Decompression goes first so any diplopia it introduces gets corrected by the strabismus surgery that follows, rather than fixing alignment first only to have a later decompression undo it. Eyelid surgery comes last because eyelid position is sensitive to both globe position and ocular alignment: operating on the lids before the globe and muscles settle into their final position risks a result that won't hold.

High-Yield Pearls

• Color vision testing screens for compressive optic neuropathy earlier and more sensitively than visual acuity.
• A positive forced duction test in a TED patient with restricted upgaze confirms mechanical restriction (typically a fibrotic inferior rectus), not a neurogenic or myasthenic cause.
• IV steroids are chosen over oral for active moderate-to-severe disease because of their faster onset and better safety/efficacy profile at the doses needed.
• Reordering the staged surgical sequence is a classic exam trap: decompression always comes first.

Related Topics

Continue exploring Oculoplastics & Orbit: